Literature DB >> 27913079

Rash Decisions: An Approach to Dangerous Rashes Based on Morphology.

Jamie Santistevan1, Brit Long2, Alex Koyfman3.   

Abstract

BACKGROUND: Rash is a common complaint in the emergency department. Many causes of rash are benign; however, some patients may have a life-threatening diagnosis.
OBJECTIVE: This review will present an algorithmic approach to rashes, focusing on life-threatening causes of rash in each category. DISCUSSION: Rash is common, with a wide range of etiologies. The differential is broad, consisting of many conditions that are self-resolving. However, several conditions associated with rash are life threatening. Several keys can be utilized to rapidly diagnose and manage these deadly rashes. Thorough history and physical examination, followed by consideration of red flags, are essential. This review focuses on four broad categories based on visual and tactile characteristic patterns of rashes: petechial/purpuric, erythematous, maculopapular, and vesiculobullous. Rashes in each morphologic group will be further categorized based on clinical features such as the presence or absence of fever and distribution of skin lesions.
CONCLUSIONS: Rashes can be divided into petechial/purpuric, erythematous, maculopapular, and vesiculobullous. After this differentiation, the presence of fever and systemic signs of illness should be assessed. Through the breakdown of rashes into these classes, emergency providers can ensure deadly conditions are considered. Published by Elsevier Inc.

Entities:  

Keywords:  erythema; maculopapular; petechiae; purpura; rash; vesiculobullous

Mesh:

Year:  2016        PMID: 27913079     DOI: 10.1016/j.jemermed.2016.10.027

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  1 in total

1.  Challenges in Evaluating Pediatric Fever and Rash in the Era of COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C).

Authors:  Taylor Jarvill; Priyanka Lauber; Samuel Umaru; Tibisay Villalobos; Susan K Yaeger
Journal:  Cureus       Date:  2022-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.